FDA Approves Enhertu for HR+/HER2-low Breast Cancer: Key Trial Results & Insights Breast Cancer 3 Mins Read FDA Approves Enhertu for HR-Positive, HER2-Low and HER2-Ultralow Breast Cancer: A New Milestone in Treatment Published: February 20, 2025 On…
